Top

World Journal of Urology

Published in:

01-08-2011 | Original Article

External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

Authors: Virginia Hernández, E. De La Peña, M. D. Martin, C. Blázquez, F. J. Diaz, C. Llorente

Published in: World Journal of Urology | Issue 4/2011

Abstract

Purpose

To perform an external validation of the EORTC risk tables and to evaluate their applicability in the patients of our institution by comparing the actual risk of recurrence and progression in our series to those obtained through the application of the EORTC tables.

Methods

Retrospective study, based on a prospective cohort of 417 patients in follow-up with primary TaT1 bladder tumors, operated on in our center between 1998 and 2008 and collected in our database. Risk scores were assigned depending on the tumor characteristics to divide our series into four risk groups according to these ratings. An analysis of survival was carried out to calculate the probability of recurrence by the method of Kaplan–Meier.

Results

A total of 417 patients with a median follow-up of 59 months were studied. The overall recurrence and progression rates of our series were 25.95% (21.97–30.49) and 4.86% (3.16–7.43) at 1 year and 53.46% (48.06–59.05) and 8.43% (5.95–11.86) at 5 years, respectively. When we compare our rates of recurrence and progression by groups with the corresponding values from Sylvester’s publication, an overlapping of the confidence intervals between both populations is detected.

Conclusions

In terms of the applicability of the EORTC risk tables in our patients’ population, we conclude that these tables predict accurately the clinical course of patients with NMIBC. Due to the sample size of our study, we can only validate the recurrence model of the EORTC tables.

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–477PubMedCrossRef

Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R (1995) Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 27(2):110–116PubMed

Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, De Pauw M, Sylvester R, Cheuvart B (1992) Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J Urol 148(2 Pt 1):297–301PubMed

Kurth K, Tunn U, Ay R, Schroder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R (1997) Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158(2):378–384PubMedCrossRef

Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153(3 Pt 2):934–941PubMed

Witjes JA, v d Meijden AP, Collette L, Sylvester R, Debruyne FM, van Aubel A, Witjes WP (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52(3):403–410PubMedCrossRef

Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149(4):749–752PubMed

Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27(3):295–300PubMedCrossRef

Donat SM, North A, Dalbagni G, Herr HW (2004) Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 171(2 Pt 1):636–639PubMedCrossRef

10.

Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67(6):1216–1223PubMedCrossRef

11.

Hernandez V, Alvarez M, de la Pena E, Amaruch N, Martin MD, de la Morena JM, Gomez V, Llorente C (2009) Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology 73(6):1306–1310PubMedCrossRef

12.

Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170(2 Pt 1):438–441PubMedCrossRef

13.

Ploeg M, Aben KK, Kiemeney LA (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27(3):289–293PubMedCrossRef

14.

Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46(17):3040–3052. doi:S0959-8049(10)00878-6 PubMedCrossRef

15.

La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F (2010) Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 21(6):1323–1360PubMedCrossRef

16.

Samanic C, Kogevinas M, Dosemeci M, Malats N, Real FX, Garcia-Closas M, Serra C, Carrato A, Garcia-Closas R, Sala M, Lloreta J, Tardon A, Rothman N, Silverman DT (2006) Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev 15(7):1348–1354PubMedCrossRef

17.

Zaak D, Burger M, Otto W, Bastian PJ, Denzinger S, Stief CG, Buchner H, Hartmann A, Wieland WF, Shariat SF, Fritsche HM (2010) Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. BJU Int 106(3):342–348PubMedCrossRef

18.

Saika T, Tsushima T, Nasu Y, Miyaji Y, Saegusa M, Takeda K, Kumon H (2010) Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study. World J Urol 28(4):413–418PubMedCrossRef

19.

Chiong E, Esuvaranathan K (2010) New therapies for non-muscle-invasive bladder cancer. World J Urol 28(1):71–78PubMedCrossRef

20.

Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164(3 Pt 1):680–684PubMedCrossRef

21.

Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Rabadan M, Astobieta A, Montesinos M, Isorna S, Muntanola P, Gimeno A, Blas M, Martinez-Pineiro JA (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182(5):2195–2203PubMedCrossRef

Title: External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer
Authors: Virginia Hernández
E. De La Peña
M. D. Martin
C. Blázquez
F. J. Diaz
C. Llorente
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 4/2011
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-010-0635-2

At a glance: The STEP trials

Springer Medicine

External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

No need for systemic heparinization during laparoscopic donor nephrectomy with short warm ischemia time

Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat

No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study

Long-term experience with early single Mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial

Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis

Erratum to: No need for systemic heparinization during laparoscopic donor nephrectomy with short warm ischemia time